You are here: Industry Insights > Remdesivir

News List

Japanese regulator approves Gilead’s remdesivir to treat Covid-19 pharmaceutical-technology
May 11, 2020
Gilead Sciences has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW) for its antiviral drug remdesivir, under the brand name Veklury, to treat Covid-19 infection.
Japan Approves Remdesivir For Use On Severe COVID-19 Patients forbes.com
May 08, 2020
Japan approved the antiviral drug Remdesivir of the Gilead Sciences for the treatment of severe COVID-19 patients.
Gilead scouting for partners in India, Pak for remdesivir expresspharma
May 08, 2020
Recent clinical trial results and the decision by the US Food and Drug Administration (FDA) to issue ”Emergency Use Authorisation” for remdesivir have highlighted the urgency of this work and the importance of planning for access to remdesivir globally.
EMA Initiates ‘Rolling Review’ of Remdesivir, Potential COVID-19 Treatment europeanpharmaceuticalreview
May 07, 2020
The EMA’s human medicines committee has announced it has begun a rolling review of remdesivir for the treatment of COVID-19, to examine its safety and effectiveness.
Gilead’s anti-viral remdesivir may be found effective against coronavirus expresspharma
May 06, 2020
The company is in discussions with some of the world’s leading chemical and pharmaceutical manufacturing companies about their ability, under voluntary licenses, to produce remdesivir for Europe, Asia and the developing world through at least 2022.
FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment americanpharmaceuticalreview
May 05, 2020
The U.S. Food and Drug Administration (FDA) issued an emergency use authorization for the investigational antiviral drug remdesivir for the treatment of suspected or laboratory-confirmed COVID-19 in adults and children hospitalized with severe disease.
Gilead Granted EUA for Remdesivir in COVID-19 contractpharma
May 04, 2020
Facilitates broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease.
Gilead announces primary endpoints met in Phase III remdesivir trial europeanpharmaceuticalreview
April 30, 2020
Gilead has said that topline results for clinical recovery have been demonstrated in a Phase III trial of remdesivir, tested in COVID-19 patients.
Gilead says leaked Covid-19 trial data of remdesivir inconclusive Pharmaceutical-Technology.
April 26, 2020
Gilead’s remdesivir has failed to show benefit in a clinical trial conducted to treat Covid-19 patients in China, according to data the World Health Organization (WHO) accidentally posted on its website.
Trial of Gilead’s potential coronavirus treatment running ahead of schedule – researcher expresspharma
April 26, 2020
Preliminary findings from the randomized trial of the antiviral drug remdesivir, begun in February by the National Institute of Allergy and Infectious Diseases (NIAID), could come even sooner, lead researcher Dr Andre Kalil told Reuters.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 14 15 Next page